Please check your internet connection and try again.
# IV Hydrocortisone for Acute Asthma
## Overview
Hydrocortisone is a short-acting systemic corticosteroid used when rapid anti-inflammatory action is required. In the setting of acute asthma, it is reserved for patients unable to tolerate oral (PO) medications or those with severe/life-threatening presentations. Systemic steroids generally require 4–6 hours to show clinical improvement.
## Primary Indications
* Management of acute, severe asthma exacerbations not responding to initial inhaled beta-agonists and ipratropium.
* Patients with nausea, vomiting, or altered mental status preventing PO intake.
## Adult Dosing
* **Initial Dose:** 100 mg IV every 6–8 hours.
* **Maximum Dose:** No specific ceiling, but clinical efficacy plateaus; doses exceeding 400 mg/day are rarely justified for asthma.
## Pediatric Dosing
* **Initial Dose:** 2–4 mg/kg IV every 6 hours.
* **Maximum Dose:** 100 mg per dose.
* *Note: Dosing should align with institutional protocols or PALS guidelines.*
## Dose Adjustments
* **Renal/Hepatic Impairment:** No standard dosage adjustments required for acute, short-term utilization.
* **Transition:** Switch to oral prednisone/prednisolone as soon as the patient can tolerate PO medications.
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to hydrocortisone or any component of the formulation.
## Adverse Effects
* **Common:** Hyperglycemia (common even in non-diabetics), agitation, insomnia, hypertension, Fluid retention.
* **Serious:** Acute psychosis, anaphylaxis, secondary infection risk (with prolonged use).
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., Phenytoin, Rifampin):** May increase metabolic clearance of hydrocortisone, reducing efficacy.
* **NSAIDs:** Increased risk of gastrointestinal ulceration/bleeding.
* **Antidiabetic Agents:** Corticosteroids may antagonize hypoglycemic effects; increased monitoring required.
## Monitoring
* **Glucose:** Monitor blood glucose levels, particularly in patients with diabetes or those on high-dose therapy.
* **Clinical Status:** Monitor respiratory rate, oxygen saturation, and peak expiratory flow (PEF) or FEV1.
* **Hypokalemia:** Assess serum electrolytes, especially if the patient is on concomitant high-dose beta-agonists or diuretics.
## Clinical Pearls
* **Oral vs. IV:** Oral systemic corticosteroids are equivalent to IV administration (e.g., oral prednisone) in efficacy for acute asthma. Use PO whenever feasible to reduce costs and line access requirements.
* **Onset:** Do not delay bronchodilator therapy; steroids do not provide immediate bronchodilation.
* **Taper:** For short, acute bursts (usually <7–10 days), a taper is generally not required; the medication can be discontinued once the exacerbation is resolved.
***
**Educational Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and dose calculations against authoritative resources (e.g., Lexicomp, Micromedex, or local pharmacy guidelines) before administration.
